ospital-Acquired Infection Therapeutics Market by Drug Type (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) 2016-2020
[ClickPress, Tue Mar 07 2017] The global hospital-acquired infection therapeutics market is estimated to reach USD 4.1 Billion in 2020, growing at a CAGR of 5.1% from 2016 to 2020, due to higher prevalence of hospital infections and demand for anti-infective drugs worldwide.
Browse Hospital-Acquired Infection Therapeutics Market by Drug Type (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/hospital-infection-therapeutics-market/
Hospital-acquired or hospital-associated infections (HAI) or nosocomial infections are contracted from the environment or staff of a healthcare facility. It can also spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. HAIs are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (e.g., ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). While antibiotic drugs to treat diseases caused by gram-positive MRSA are available, few effective drugs are available for Acinetobacter bacteria that are evolving and becoming immune to existing antibiotics. The major types of hospital infections prevalent worldwide are hospital-acquired pneumonia, urinary tract infections and surgical site infections. Hospital infections are mainly treated with antimicrobial drugs that help patients suffering from bacterial, viral or other microbial infections.
The global hospital-acquired infection therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (antibacterial, antifungal and antiviral drugs), clinical pipeline analysis of phase 1, 2 and 3 drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), indications (blood stream infections, gastrointestinal disorders, HAP, SSIs, UTIs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global hospital-acquired infection therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hospital-acquired infection therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global hospital-acquired infection therapeutics market and included in this report are Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi S.A.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hospital-infection-therapeutics-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043